Towards Personalised Medicine in Metastatic Prostate Cancer

Prostate cancer is one of the most commonly diagnosed cancers in men and a leading cause of cancer-related death, with survival dropping sharply once the disease spreads beyond the prostate. My research aims to improve outcomes for these patients by moving away from a "one-size-fits-all" treatment approach towards more personalised medicine. To do this, I'm analysing advanced medical scans called PSMA PET and SPECT, which show where cancer is located and how it responds to treatment. This scan information is used in three ways: to identify higher-risk patients who may need more intensive treatment, to automatically detect and measure tumours using AI, and to estimate radiation dose delivered to tumours and healthy organs to guide radiation-based treatments.

This project aims to support more personalised treatment for advanced prostate cancer by improving treatment response assessment, identifying patients at higher risk of poor outcomes, and establishing relationships between radiation dose and treatment response. AI-assisted imaging tools and improved dosimetry methods may also enable more consistent disease assessment and better tailoring of therapy to individual patients. Together, these advances could improve patient outcomes, reduce unnecessary treatment and toxicity, and support more efficient use of radioligand therapy within the health system.

Total: 0.0 / 10

Patient Outcome Benefit: 0.0 / 10

Patient Financial Benefit: 0.0 / 10

Healthcare System Benefit: 0.0 / 10

Required: $0

Committed: $0

Progress: 0%